secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZIMMER BIOMET HOLDINGS, INC. (ZBH)
CIK:        0001136869
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0000950170-24-092253
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zimmer Biomet Q2 adjusted EPS $2.01 beats; revenue +5.6% CC; full-year guidance reaffirmed
--------------------------------------------------------------------------------

- Q2 net sales $1.942B (+5.6% constant currency); diluted EPS $1.18 GAAP, $2.01 adjusted, exceeding expectations.
- Net earnings $242.8M GAAP; adjusted net earnings $415.0M.
- FY 2024 reported revenue guidance lowered to 4.0%-5.0% on FX; CC revenue growth 5.0%-6.0% and adjusted EPS $8.00-$8.15 reaffirmed.
- Signed definitive agreement to acquire OrthoGrid Systems (AI hip guidance); also entered THINK Surgical and CBRE partnerships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1136869/000095017024092253/0000950170-24-092253-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1136869/000095017024092253/zbh-20240807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-092253

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer